HIV molecular immunology database

 

Search the Epitope Variant and Escape Mutation Database

Help


Found 3 matching records:

Displaying record number 55763

HXB2 Location  Gag(77-85)   Gag Epitope Map
View variants at this location
Epitope SLYNTVATL   Epitope Alignment
Variants
SLfNTVATL   susceptible form
SLYNlVATL   susceptible form
SLfNlVATL   susceptible form
SiYNlVATL   susceptible form
Epitope Name SL9
Species (MHC/HLA human, transgenic mouse(A2)

Variant Details

Showing all: 4 variant(s).


Variant ID.  76
Epitope Seq.  SLYNTVATL
Variant Seq.  SLfNTVATL
Mutations Y/F
Epitope Location Y3F
HXB2 Location Y79F
Mutation Type SF: susceptible form
Method CD8 T-cell Elispot - IFNy, Chromium-release assay
Note To identify immunogenically optimized epitopes for use in vaccines, mutants of SL9 were tested in transgenic mice. SLYNTVATL and most common mutant, SLfNTVATL, were weakly immunogenic or cross-reactive. 3 mutants, SLYNlVATL, SLfNlVATL and SiYNlVATL were highly immunogenic. Peptide SiYNlVATL with the additional L2I change allowed great cross-reactivity to the consensus.


Variant ID.  77
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYNlVATL
Mutations T/L
Epitope Location T5L
HXB2 Location T81L
Mutation Type SF: susceptible form
Method CD8 T-cell Elispot - IFNy, Chromium-release assay
Note To identify immunogenically optimized epitopes for use in vaccines, mutants of SL9 were tested in transgenic mice. SLYNTVATL and most common mutant, SLfNTVATL, were weakly immunogenic or cross-reactive. 3 mutants, SLYNlVATL, SLfNlVATL and SiYNlVATL were highly immunogenic. Peptide SiYNlVATL with the additional L2I change allowed great cross-reactivity to the consensus.


Variant ID.  78
Epitope Seq.  SLYNTVATL
Variant Seq.  SLfNlVATL
Mutations Y/F T/L
Epitope Location Y3F T5L
HXB2 Location Y79F T81L
Mutation Type SF: susceptible form
Method CD8 T-cell Elispot - IFNy, Chromium-release assay
Note To identify immunogenically optimized epitopes for use in vaccines, mutants of SL9 were tested in transgenic mice. SLYNTVATL and most common mutant, SLfNTVATL, were weakly immunogenic or cross-reactive. 3 mutants, SLYNlVATL, SLfNlVATL and SiYNlVATL were highly immunogenic. Peptide SiYNlVATL with the additional L2I change allowed great cross-reactivity to the consensus.


Variant ID.  79
Epitope Seq.  SLYNTVATL
Variant Seq.  SiYNlVATL
Mutations L/I T/L
Epitope Location L2I T5L
HXB2 Location L78I T81L
Mutation Type SF: susceptible form
Method CD8 T-cell Elispot - IFNy, Chromium-release assay
Note To identify immunogenically optimized epitopes for use in vaccines, mutants of SL9 were tested in transgenic mice. SLYNTVATL and most common mutant, SLfNTVATL, were weakly immunogenic or cross-reactive. 3 mutants, SLYNlVATL, SLfNlVATL and SiYNlVATL were highly immunogenic. Peptide SiYNlVATL with the additional L2I change allowed great cross-reactivity to the consensus.

References

Blondelle2008 Sylvie E. Blondelle, Rosa Moya-Castro, Keiko Osawa, Kim Schroder, and Darcy B. Wilson. Immunogenically Optimized Peptides Derived from Natural Mutants of HIV CTL Epitopes and Peptide Combinatorial Libraries. Biopolymers, 90(5):683-694, 2008. PubMed ID: 18481808. Show all entries for this paper.


Displaying record number 56141

HXB2 Location  Gag(151-159)   Gag Epitope Map
View variants at this location
Epitope TLNAWVKVV   Epitope Alignment
Variants
TLNAWVKVi   diminished response
TLNAWVKaV   susceptible form
TLNAWVKai   susceptible form
Epitope Name TV9
Species (MHC/HLA human, transgenic mouse(A2)

Variant Details

Showing all: 3 variant(s).


Variant ID.  80
Epitope Seq.  TLNAWVKVV
Variant Seq.  TLNAWVKVi
Mutations V/I
Epitope Location V9I
HXB2 Location V159I
Mutation Type DR: diminished response
Method CD8 T-cell Elispot - IFNy, Chromium-release assay
Note To identify immunogenically optimized epitopes for use in vaccines, mutants of TV9 were tested in transgenic mice. Natural TV9 mutants tested in transgenic HLA-A*02 mice showed the following responses - the common mutant V9I, TLNAWVKVi was less immunogenic and had low cross-reactivity. TLNAWVKaV (most cross-reactive) and TLNAWVKai were highly immunogenic and cross-reactive to the consensus.


Variant ID.  81
Epitope Seq.  TLNAWVKVV
Variant Seq.  TLNAWVKaV
Mutations V/A
Epitope Location V8A
HXB2 Location V158A
Mutation Type SF: susceptible form
Method CD8 T-cell Elispot - IFNy, Chromium-release assay
Note To identify immunogenically optimized epitopes for use in vaccines, mutants of TV9 were tested in transgenic mice. Natural TV9 mutants tested in transgenic HLA-A*02 mice showed the following responses - the common mutant V9I, TLNAWVKVi was less immunogenic and had low cross-reactivity. TLNAWVKaV (most cross-reactive) and TLNAWVKai were highly immunogenic and cross-reactive to the consensus.


Variant ID.  82
Epitope Seq.  TLNAWVKVV
Variant Seq.  TLNAWVKai
Mutations V/A V/I
Epitope Location V8A V9I
HXB2 Location V158A V159I
Mutation Type SF: susceptible form
Method CD8 T-cell Elispot - IFNy, Chromium-release assay
Note To identify immunogenically optimized epitopes for use in vaccines, mutants of TV9 were tested in transgenic mice. Natural TV9 mutants tested in transgenic HLA-A*02 mice showed the following responses - the common mutant V9I, TLNAWVKVi was less immunogenic and had low cross-reactivity. TLNAWVKaV (most cross-reactive) and TLNAWVKai were highly immunogenic and cross-reactive to the consensus.

References

Blondelle2008 Sylvie E. Blondelle, Rosa Moya-Castro, Keiko Osawa, Kim Schroder, and Darcy B. Wilson. Immunogenically Optimized Peptides Derived from Natural Mutants of HIV CTL Epitopes and Peptide Combinatorial Libraries. Biopolymers, 90(5):683-694, 2008. PubMed ID: 18481808. Show all entries for this paper.


Displaying record number 56140

HXB2 Location  Pol(464-472)   Pol Epitope Map
View variants at this location
Epitope ILKEPVHGV   Epitope Alignment
Variants
ILKdPVHGV   diminished response
ILKEPVHrV   susceptible form
ILrEPiHGV   susceptible form
ILKEPVHGi   susceptible form
Epitope Name IV9
Species (MHC/HLA human, transgenic mouse(A2)

Variant Details

Showing all: 4 variant(s).


Variant ID.  83
Epitope Seq.  ILKEPVHGV
Variant Seq.  ILKdPVHGV
Mutations E/D
Epitope Location E4D
HXB2 Location E467D
Mutation Type DR: diminished response
Method CD8 T-cell Elispot - IFNy, Chromium-release assay
Note To identify immunogenically optimized epitopes for use in vaccines, mutants of IV9 were tested in transgenic mice. Mutants of epitope IV9 when tested in transgenic mice, showed that the consensus was strongly immunogenic, but the most common mutant, ILKdPVHGV was not especially immunogenic or cross-reactive. Rare mutant, ILKEPVHrV, was highly immunogenic, and cross-reactive to the consensus. Sequences ILrEPiHGV and ILKEPVHGi were also cross-reactive to the consensus.


Variant ID.  84
Epitope Seq.  ILKEPVHGV
Variant Seq.  ILKEPVHrV
Mutations G/R
Epitope Location G8R
HXB2 Location G471R
Mutation Type SF: susceptible form
Method CD8 T-cell Elispot - IFNy, Chromium-release assay
Note To identify immunogenically optimized epitopes for use in vaccines, mutants of IV9 were tested in transgenic mice. Mutants of epitope IV9 when tested in transgenic mice, showed that the consensus was strongly immunogenic, but the most common mutant, ILKdPVHGV was not especially immunogenic or cross-reactive. Rare mutant, ILKEPVHrV, was highly immunogenic, and cross-reactive to the consensus. Sequences ILrEPiHGV and ILKEPVHGi were also cross-reactive to the consensus.


Variant ID.  85
Epitope Seq.  ILKEPVHGV
Variant Seq.  ILrEPiHGV
Mutations K/R V/I
Epitope Location K3R V6I
HXB2 Location K466R V469I
Mutation Type SF: susceptible form
Method CD8 T-cell Elispot - IFNy, Chromium-release assay
Note To identify immunogenically optimized epitopes for use in vaccines, mutants of IV9 were tested in transgenic mice. Mutants of epitope IV9 when tested in transgenic mice, showed that the consensus was strongly immunogenic, but the most common mutant, ILKdPVHGV was not especially immunogenic or cross-reactive. Rare mutant, ILKEPVHrV, was highly immunogenic, and cross-reactive to the consensus. Sequences ILrEPiHGV and ILKEPVHGi were also cross-reactive to the consensus.


Variant ID.  86
Epitope Seq.  ILKEPVHGV
Variant Seq.  ILKEPVHGi
Mutations V/I
Epitope Location V9I
HXB2 Location V472I
Mutation Type SF: susceptible form
Method CD8 T-cell Elispot - IFNy, Chromium-release assay
Note To identify immunogenically optimized epitopes for use in vaccines, mutants of IV9 were tested in transgenic mice. Mutants of epitope IV9 when tested in transgenic mice, showed that the consensus was strongly immunogenic, but the most common mutant, ILKdPVHGV was not especially immunogenic or cross-reactive. Rare mutant, ILKEPVHrV, was highly immunogenic, and cross-reactive to the consensus. Sequences ILrEPiHGV and ILKEPVHGi were also cross-reactive to the consensus.

References

Blondelle2008 Sylvie E. Blondelle, Rosa Moya-Castro, Keiko Osawa, Kim Schroder, and Darcy B. Wilson. Immunogenically Optimized Peptides Derived from Natural Mutants of HIV CTL Epitopes and Peptide Combinatorial Libraries. Biopolymers, 90(5):683-694, 2008. PubMed ID: 18481808. Show all entries for this paper.


Questions or comments? Contact us at immuno@lanl.gov
 
Managed by Triad National Security, LLC for the U.S. Department of Energy’s National Nuclear Security Administration
Copyright © 2022 Triad National Security, LLC | Disclaimer/Privacy

Dept of Health & Human Services Los Alamos National Institutes of Health